These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32246516)

  • 21. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.
    Ardigò M; Giuliani A; de Felice C; Mastroianni A; Berardesca E
    J Drugs Dermatol; 2008 Oct; 7(10):935-9. PubMed ID: 19112756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
    J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.
    Thaçi D; Papp K; Marcoux D; Weibel L; Pinter A; Ghislain PD; Landells I; Hoeger PH; Unnebrink K; Seyger MMB; Williams DA; Rubant S; Philipp S
    Br J Dermatol; 2019 Dec; 181(6):1177-1189. PubMed ID: 31017657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.
    Menter A; Bhutani T; Ehst B; Elewski B; Jacobson A
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1289-1302. PubMed ID: 35672564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab-related alopecia in a patient affected by psoriasis.
    Melé-Ninot G; Expósito-Serrano V; Quintana Codina M; Iglesias Sancho M; Sánchez-Regaña M; Umbert Millet P; Salleras Redonnet M
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of severe facial psoriasis with adalimumab.
    Noiles K; Vender R
    J Drugs Dermatol; 2008 Dec; 7(12):1165-7. PubMed ID: 19137771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab in the management of palmoplantar psoriasis.
    Ghate JV; Alspaugh CD
    Dermatol Online J; 2009 Jul; 15(7):15. PubMed ID: 19903443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of nail psoriasis with adalimumab: an open label unblinded study.
    Rigopoulos D; Gregoriou S; Lazaridou E; Belyayeva E; Apalla Z; Makris M; Katsambas A; Ioannides D
    J Eur Acad Dermatol Venereol; 2010 May; 24(5):530-4. PubMed ID: 19807825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary Central Nervous System Lymphoma in a Patient on Adalimumab Therapy for Chronic Plaque Psoriasis.
    Farah RA; Alduaij A; Ugas C; Navarro R
    World Neurosurg; 2020 Jul; 139():260-263. PubMed ID: 32247793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution.
    Kamiya K; Karakawa M; Komine M; Kishimoto M; Sugai J; Ohtsuki M
    J Dermatol; 2019 Mar; 46(3):199-205. PubMed ID: 30672612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis.
    Saraceno R; Pietroleonardo L; Mazzotta A; Zangrilli A; Bianchi L; Chimenti S
    Expert Opin Biol Ther; 2013 Apr; 13(4):469-73. PubMed ID: 23157654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
    Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab: in plaque psoriasis.
    Croom KF; McCormack PL
    Am J Clin Dermatol; 2009; 10(1):43-50. PubMed ID: 19170412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study.
    Richetta AG; Mattozzi C; Giancristoforo S; D'Epiro S; Cantisani C; Macaluso L; Salvi M; Calvieri S
    Clin Ter; 2012; 163(2):e61-6. PubMed ID: 22555836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
    Thaçi D; Unnebrink K; Sundaram M; Sood S; Yamaguchi Y
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):353-360. PubMed ID: 24846518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails.
    Handa S
    Indian J Dermatol Venereol Leprol; 2010; 76(6):634-44. PubMed ID: 21079306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.